Antidotes for toxicological emergencies: A practical review

American Journal of Health-System Pharmacy

Volumn 69, Issue 3, 2012, Pages 199-212

  Marraffa, Jeanna M ^a,b   Cohen, Victor ^c,d   Howland, Mary Ann ^e,f,g  

^a Upstate New York Poison Center   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c LONG ISLAND UNIVERSITY   (United States)

^d MAIMONIDES MEDICAL CENTER   (United States)

^e ST JOHN'S UNIVERSITY   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NEW YORK CITY POISON CONTROL CENTER   (United States)

Author keywords

Antidotes; Dosage; Drugs; Hospitals; Pharmaceutical services; Pharmacists, hospital; Pharmacy, institutional, hospital; Poisoning; Protocols

Indexed keywords

4 METHYLPYRAZOLE; ACETYLCYSTEINE; ALCOHOL; ALCOHOL DEHYDROGENASE; AMYL NITRITE; ANTIDOTE; BENZODIAZEPINE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHLORIDE; DIETHYLENE GLYCOL; DIGITALIS; DIGOXIN ANTIBODY F(AB) FRAGMENT; ETHYLENE GLYCOL; FLUMAZENIL; FOLIC ACID; GLUCAGON; GLUCONATE CALCIUM; GLUCOSE; HYDROXOCOBALAMIN; INDUSTRIAL TOXIC SUBSTANCE; INSULIN; LIPID EMULSION; METHANOL; POTASSIUM; PYRIDOXINE; SODIUM NITRITE; SODIUM THIOSULFATE; THIAMINE; UNINDEXED DRUG;

ALCOHOL INTOXICATION; ALLERGIC REACTION; CALCIUM BLOOD LEVEL; CARDIOTOXICITY; CHROMATURIA; CYANIDE POISONING; DIASTOLIC BLOOD PRESSURE; DIGITALIS INTOXICATION; DRUG BIOAVAILABILITY; DRUG OVERDOSE; DYSPHAGIA; ELECTROCARDIOGRAPHY; EMERGENCY CARE; ERYTHEMA; GASTROINTESTINAL DISEASE; HEADACHE; HEART HEMODYNAMICS; HEMODIALYSIS; HOSPITAL; HUMAN; HYPERINSULINEMIA EUGLYCEMIA THERAPY; INJECTION SITE REACTION; INTOXICATION; METHEMOGLOBINEMIA; MORBIDITY; MORTALITY; NONHUMAN; PATIENT MONITORING; PHARMACIST; POTASSIUM BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; RESCUE PERSONNEL; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; UNITED STATES;

EID: 84857588927     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110014     Document Type: Review

References (144)

1. Centers for Disease Control and Prevention. Unintentional poisoning deaths - United States, 1999-2004. MMWR Morb Mortal Wkly Rep. 2007; 56:93-6.
2. Bronstein AC, Spyker DA, Cantilena LR Jr et al. 2009 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th annual report. Clin Toxicol (Phila). 2010; 48:979-1178.
3. Linakis JG, Frederick KA. Poisoning deaths not reported to the regional poison center. Ann Emerg Med. 1993; 22:1822-8. (Pubitemid 23346155)
4. Shepherd G, Klein-Schwartz W. Accidental and suicidal adolescent poisoning deaths in the US, 1979-1994. Arch Pediatr Adolesc Med. 1998; 152:1181-5. (Pubitemid 28558103)
5. Dart RC, Borron SW, Caravati EM et al. Antidote Summit Authorship G. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2009; 54:386-94.e1.
6. Brent J, McMartin K, Phillips S et al., for the Methylpyrazole for Toxic Alcohols Study Group. Fomepizole for the treatment of methanol poisoning. N Engl J Med. 2001; 344:424-9. (Pubitemid 32128675)
7. Brent J, McMartin K, Phillips S et al., for the Methylpyrazole for Toxic Alcohols Study Group. Fomepizole for the treatment of ethylene glycol poisoning. N Engl J Med. 1999; 340:832-8. (Pubitemid 29142626)
8. Barceloux DG, Bond GR, Krenzelok EP et al., for the American Academy of Clinical Toxicology Ad Hoc Committee on the Treatment Guidelines for Methanol Poisoning. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol. 2002; 40:415-46. (Pubitemid 34976720)
9. Bronstein AC, Spyker DA, Cantilena LR Jr et al. 2008 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th annual report. Clin Toxicol (Phila). 2009; 47:911-1084.
10. McMartin KE, Brent J, META Study Group. Pharmacokinetics of fomepizole (4MP) in patients. J Toxicol Clin Toxicol. 1998; 36:450-1.
11. Sanaei-Zadeh H, Zamani N, Shadnia S. Outcomes of visual disturbances after methanol poisoning. Clin Toxicol. 2011; 49:102-7.
12. McMartin KE, Heath A. Treatment of ethylene glycol poisoning with intravenous 4-methylpyrazole. N Engl J Med. 1989; 320:125. (Pubitemid 19033087)
13. Hanif M, Mobarak MR, Ronan A et al. Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. BMJ. 1995; 311:88-91.
14. Okuonghae HO, Ighogboja IS, Lawson JO et al. Diethylene glycol poisoning in Nigerian children. Ann Trop Paediatr. 1992; 12:235-8.
15. Rollins YD, Filley CM, McNutt JT et al. Fulminant ascending paralysis as a delayed sequela of diethylene glycol (Sterno) ingestion. Neurology. 2002; 59:1460-3. (Pubitemid 35286011)
16. Marraffa JM, Holland MG, Stork CM et al. Diethylene glycol: widely used solvent presents serious poisoning potential. J Emerg Med. 2007; 35:401-6.
17. Hasbani MJ, Sansing LH, Perrone J et al. Encephalopathy and peripheral neuropathy following diethylene glycol ingestion. Neurology. 2005; 64:1273-5.
18. Alfred S, Coleman P, Harris D et al. Delayed neurologic sequelae resulting from epidemic diethylene glycol poisoning. Clin Toxicol (Phila). 2005; 43:155-9.
19. Hari P, Jain Y, Kabra SK. Fatal encephalopathy and renal failure caused by diethylene glycol poisoning. J Trop Pediatr. 2006; 52:442-4. (Pubitemid 44964234)
20. Landry GM, Martin S, McMartin KE. Diglycolic acid is the nephrotoxic metabolite in diethylene glycol poisoning inducing necrosis in human proximal tubule cells in vitro. Toxicol Sci. 2011; 123:374-83.
21. Jacobsen D, McMartin KE. Antidotes for methanol and ethylene glycol poisoning. J Toxicol Clin Toxicol. 1997; 35:127-43. (Pubitemid 27130584)
22. Wallemacq PE, Vanbinst R, Haufroid V et al. Plasma and tissue determination of 4-methylpyrazole for pharmacokinetic analysis in acute adult and pediatric methanol/ethylene glycol poisoning. Ther Drug Monit. 2004; 26:258-62. (Pubitemid 38703010)
23. Antizol (fomepizole) injection product information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 2007 Jan.
24. Noker PE, Eells JT, Tephly TR. Methanol toxicity: treatment with folic acid and 5-formyl tetrahydrofolic acid. Alcohol Clin Exp Res. 1980; 4:378-83. (Pubitemid 10030491)
25. Noker PE, Tephly TR. The role of folates in methanol toxicity. Adv Exp Med Biol. 1980; 132:305-15.
26. Nath R, Thind SK, Murthy MS et al. Role of pyridoxine in oxalate metabolism. Ann N Y Acad Sci. 1990; 585:274-84. 27. Sharma S, Sidhu H, Narula R et al. Comparative studies on the effect of vitamin A, B1 and B6 deficiency on oxalate metabolism in male rats. Ann Nutr Metab. 1990; 34:104-11. (Pubitemid 20170355)
27. Kerns W II. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin North Am. 2007; 25:309-31.
28. DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev. 2004; 23:223-38. (Pubitemid 41018276)
29. Levine M, Boyer EW, Pozner CN et al. Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007; 35:2071-5. (Pubitemid 47326443)
30. Boyer EW, Duic PA, Evans A. Hyperinsulinemia/euglycemia therapy for calcium channel blocker poisoning. Pediatr Emerg Care. 2002; 18:36-7. (Pubitemid 34174344)
31. Yuan TH, Kerns WP II, Tomaszewski CA et al. Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol. 1999; 37:463-74. (Pubitemid 29387890)
32. Farah AE, Alousi AA. The actions of insulin on cardiac contractility. Life Sci. 1981; 29:975-1000. (Pubitemid 12233040)
33. Mégarbane B, Karyo S, Baud FJ. The role of insulin and glucose (hyperinsulinaemia/euglycaemia) therapy in acute calcium channel antagonist and beta-blocker poisoning. Toxicol Rev. 2004; 23:215-22. (Pubitemid 41018275)
34. Lheureux PE, Zahir S, Gris M et al. Bench-to-bedside review: hyperinsulinaemia/euglycaemia therapy in the management of overdose of calcium-channel blockers. Crit Care. 2006; 10:212.
35. Kline JA, Leonova E, Raymond RM. Beneficial myocardial metabolic effects of insulin during verapamil toxicity in the anesthetized canine. Crit Care Med. 1995; 23:1251-63.
36. Kline JA, Tomaszewski CA, Schroeder JD et al. Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine. J Pharmacol Exp Ther. 1993; 267:744-50. (Pubitemid 23352533)
37. Kerns W II, Ransom M, Tomaszewski C et al. The effects of extracellular ions on beta-blocker cardiotoxicity. Toxicol Appl Pharmacol. 1996; 137:1-7.
38. Kerns W. Antidotes in depth: insulin-euglycemia therapy. In: Nelson LS, Lewin NA, Howland MA et al., eds. Goldfrank's toxicologic emergencies. 9th ed. New York: McGraw-Hill; 2011:893-5.
39. Engebretsen KM, Kac Z, Marek KK et al. High dose insulin therapy in beta-blocker and calcium channel blocker poisoning. Clin Toxicol. 2011; 49:277-83.
40. Cyanide antidote kit (sodium nitrite injection, sodium theosulfate injection, amyl nitrite inhalants) package insert. Lake Forest, IL: Akorn, Incorporated; 2008.
41. Nithiodote (sodium nitrite injection and sodium thiosulfate injection) package insert. Scottsdale, AZ: Hope Pharmaceuticals; 2011.
42. Cyanokit (hydroxocobalamin for injection) product information. Semoy, France: Merck Sante; 2009.
43. Barillo DJ, Goode R, Esch V. Cyanide poisoning in victims of fire: analysis of 364 cases and review of the literature. J Burn Care Rehabil. 1994; 15:46-57. (Pubitemid 24050334)
44. Eckstein M, Maniscalco PM. Focus on smoke inhalation - the most common cause of acute cyanide poisoning. Prehospital Disaster Med. 2006; 21:S49-55.
45. Fortin JL, Waroux S, Giocanti JP et al. Hydroxocobalamin for poisoning caused by ingestion of potassium cyanide: a case study. J Emerg Med. 2010; 39:320-4.
46. Baud FJ, Borron SW, Mégarbane B et al. Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning. Crit Care Med. 2002; 30:2044-50.
47. Chen KK, Rose C, Clowes G. Amyl nitrite and cyanide poisoning. JAMA. 1933; 100:1921-2.
48. Chen KK, Rose C. Nitrite and thiosulfate therapy in cyanide poisoning. JAMA. 1952; 149:113-9.
49. Hall AH, Kulig KW, Rumack BH. Suspected cyanide poisoning in smoke inhalation and complications of sodium nitrite therapy. J Toxicol Clin Exp. 1989; 9:3-9. (Pubitemid 19132873)
50. Klimmek R, Krettek C, Werner HW. Ferrihaemoglobin formation by amyl nitrite and sodium nitrite indifferent species in vivo and in vitro. Arch Toxicol. 1988; 62:152-60.
51. Curry SC, Carlton MW, Raschke RA. Prevention of fetal and maternal cyanide toxicity from nitroprusside with coinfusion of sodium thiosulfate in gravid ewes. Anesth Analg. 1997; 84:1121-6. (Pubitemid 27197678)
52. Borron SW, Baud FJ, Mégarbane B et al. Hydroxocobalamin for severe acute cyanide poisoning by ingestion or inhalation. Am J Emerg Med. 2007; 25:551-8. (Pubitemid 46830859)
53. Fortin JL, Giocanti JP, Ruttimann M et al. Prehospital administration of hydroxocobalamin for smoke inhalationassociated cyanide poisoning: 8 years of experience in the Paris fire brigade. Clin Toxicol (Phila). 2006; 44(suppl 1):37-44. (Pubitemid 44451798)
54. Borron SW, Stonerook M, Reid F. Efficacy of hydroxocobalamin for the treatment of acute cyanide poisoning in adult beagle dogs. Clin Toxicol (Phila). 2006; 44(suppl 1):5-15. (Pubitemid 44451795)
55. Uhl W, Nolting A, Golor G et al. Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study. Clin Toxicol (Phila). 2006; 44(suppl 1):17-28. (Pubitemid 44451796)
56. Sutter M, Tereshchenko N, Rafii R et al. Hemodialysis complications of hydroxocobalamin: a case report. J Med Toxicol. 2010; 6:165-7.
57. Cescon DW, Juurlink DN. Discoloration of skin and urine after treatment with hydroxocobalamin for cyanide poisoning. CMAJ. 2009; 180:251.
58. Curry SC, Connor DA, Raschke RA. Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies. Ann Emerg Med. 1994; 24:65-7. (Pubitemid 24214622)
59. Beaudeux JL, Flourie F, Peynet J et al. Hydroxocobalamin and sodium thiosulfate interfere negatively with measurement of creatine kinase activity. Clin Chem. 1994; 40:2120-1. (Pubitemid 24346193)
60. Beckerman N, Leikin SM, Aitchinson R et al. Laboratory interferences with the newer cyanide antidote: hydroxocobalamin. Semin Diagn Pathol. 2009; 26:49-52.
61. Pamidi PV, DeAbreu M, Kim D et al. Hydroxocobalamin and cyanocobalamin interference on co-oximetry based hemoglobin measurements. Clin Chim Acta. 2009; 401:63-7.
62. Centers for Disease Control and Prevention. Deaths associated with a purported aphrodisiac - New York City, February 1993-May 1995. MMWR Morb Mortal Wkly Rep. 1995; 44:853-5.
63. Hickey AR, Wenger TL, Carpenter VP et al. Digoxin immune fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991; 17:590-8.
64. Woolf AD, Wenger TL, Smith TW et al. Results of multicenter studies of digoxin-specific antibody fragments in managing digitalis intoxication in the pediatric population. Am J Emerg Med. 1991; 9(2, suppl 1):16,20 [discussion 33-4].
65. Antman EM, Wenger TL, Butler VP Jr et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific fab antibody fragments. Final report of a multicenter study. Circulation. 1990; 81:1744-52. (Pubitemid 20183822)
66. Lapostolle F, Borron SW, Verdier C et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med. 2008; 34:1448-53.
67. Lapostolle F, Borron SW, Verdier C et al. Digoxin-specific fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med. 2008; 36:3014-8.
68. Slifman NR, Obermeyer WR, Aloi BK et al. Contamination of botanical dietary supplements by digitalis lanata. N Engl J Med. 1998; 339:806-11. (Pubitemid 28447454)
69. Bismuth C, Borron SW, Baud FJ et al. Immunotoxicotherapy: successes, disappointments and hopes. Hum Exp Toxicol. 1997; 16:602-8. (Pubitemid 27480882)
70. Domart Y, Bismuth C, Schermann JM et al. Digitoxin poisoning: reversing ventricular fibrillation with fab fragments of anti-digoxin antibody. Nouv Presse Med. 1982; 11:3827-30. (Pubitemid 13201890)
71. Smolarz A, Roesch E, Lenz E et al. Digoxin specific antibody (fab) fragments in 34 cases of severe digitalis intoxication. J Toxicol Clin Toxicol. 1985; 23:327-40. (Pubitemid 16183274)
72. Borron SW, Bismuth C, Muszynski J. Advances in the management of digoxin toxicity in the older patient. Drugs Aging. 1997; 10:18-33.
73. Doherty JE, Perkins WH, Flanigan WJ. The distribution and concentration of tritiated digoxin in human tissues. Ann Intern Med. 1967; 66:116-24.
74. Gibb T, Adams PC, Parnham AJ et al. Plasma digoxin: assay anomalies in Fab-treated patients. Br J Clin Pharmacol. 1983; 16:445-7. (Pubitemid 13015774)
75. Goldfrank LR. Flumazenil: a pharmacologic antidote with limited medical toxicology utility, or . . . an antidote in search of an overdose. Acad Emerg Med. 1997; 4:935-6.
76. Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. Ann Pharmacother. 1994; 28:1347-9.
77. Lheureux P, Vranckx M, Leduc D et al. Risks of flumazenil in mixed benzodiazepine-tricyclic antidepressant overdose: report of a preliminary study in the dog. J Toxicol Clin Exp. 1992; 12:43-53.
78. Mordel A, Winkler E, Almog S et al. Seizures after flumazenil administration in a case of combined benzodiazepine and tricyclic antidepressant overdose. Crit Care Med. 1992; 20:1733-4.
79. Seger DL. Flumazenil - treatment or toxin. J Toxicol Clin Toxicol. 2004; 42:209-16. (Pubitemid 38758535)
80. McEvoy GK, Snow EK, Miller J et al., eds. AHFS drug information 2009. Bethesda, MD: American Society of Health-System Pharmacists; 2009:2.
81. Romazicon (flumazenil) injection product information. Nutley, NJ: Roche Pharmaceuticals, Inc.; 2007.
82. Weinberg G. Lipid rescue resuscitation from local anaesthetic cardiac toxicity. Toxicol Rev. 2006; 25:139-45.
83. Weinberg G. Lipid infusion resuscitation for local anesthetic toxicity: proof of clinical efficacy. Anesthesiology. 2006; 105:7-8. (Pubitemid 44305184)
84. Weinberg G, Ripper R, Feinstein DL et al. Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med. 2003; 28:198-202. (Pubitemid 36618312)
85. Weinberg GL. Limits to lipid in the literature and lab: what we know, what we don't know. Anesth Analg. 2009; 108:1062-4.
86. Weinberg GL. Lipid infusion therapy: translation to clinical practice. Anesth Analg. 2008; 106:1340-2. (Pubitemid 351571057)
87. Weinberg GL, di Gregorio G, Ripper R et al. Resuscitation with lipid versus epinephrine in a rat model of bupivacaine overdose. Anesthesiology. 2008; 108:907-13. (Pubitemid 351589487)
88. Hiller DB, Gregorio GD, Ripper R et al. Epinephrine impairs lipid resuscitation from bupivacaine overdose: a threshold effect. Anesthesiology. 2009; 111:498-505.
89. Charbonneau H, Marcou TA, Mazoit JX et al. Early use of lipid emulsion to treat incipient mepivacaine intoxication. Reg Anesth Pain Med. 2009; 34:277-8.
90. Litz RJ, Roessel T, Heller AR et al. Reversal of central nervous system and cardiac toxicity after local anesthetic intoxication by lipid emulsion injection. Anesth Analg. 2008; 106:1575-7. (Pubitemid 351571096)
91. Markowitz S, Neal JM. Immediate lipid emulsion therapy in the successful treatment of bupivacaine systemic toxicity. Reg Anesth Pain Med. 2009; 34:276.
92. Rosenblatt MA, Abel M, Fischer GW et al. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006; 105:217-8. (Pubitemid 44305211)
93. Weinberg G, Hertz P, Newman J. Lipid, not propofol, treats bupivacaine overdose. Anesth Analg. 2004; 99:1875-6. (Pubitemid 39551947)
94. Bania TC, Chu J, Perez E et al. Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, calcium, and saline. Acad Emerg Med. 2007; 14:105-11. (Pubitemid 46157192)
95. Harvey M, Cave G, Hoggett K. Correlation of plasma and peritoneal diasylate clomipramine concentration with hemodynamic recovery after intralipid infusion in rabbits. Acad Emerg Med. 2009; 16:151-6.
96. Perez E, Bania TC, Medlej K et al. Determining the optimal dose of intravenous fat emulsion for the treatment of severe verapamil toxicity in a rodent model. Acad Emerg Med. 2008; 15:1284-9.
97. Tebbutt S, Harvey M, Nicholson T et al. Intralipid prolongs survival in a rat model of verapamil toxicity. Acad Emerg Med. 2006; 13:134-9. (Pubitemid 43155818)
98. Sirianni AJ, Osterhoudt KC, Calello DP et al. Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. Ann Emerg Med. 2008; 51:412-5.
99. Gueret G, Pennec JP, Arvieux CC. Hemodynamic effects of intralipid after verapamil intoxication may be due to a direct effect of fatty acids on myocardial calcium channels. Acad Emerg Med. 2007; 14:761.
100. Hiller DB, di Gregorio G, Kelly K et al. Safety of high volume lipid emulsion infusion: a first approximation of LD50 in rats. Reg Anesth Pain Med. 2010; 35:140-4.
101. Harrison PM, Keays R, Bray GP et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet. 1990; 335:1572-3. (Pubitemid 20189636)
102. Harrison PM, Wendon JA, Gimson AE et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991; 324:1852-7.
103. Keays R, Harrison PM, Wendon JA et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ. 1991; 303:1026-9.
104. Prescott LF, Illingworth RN, Critchley JA et al. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J. 1979; 2:1097-100. (Pubitemid 10249121)
105. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics. 1975; 55:871-6.
106. Rumack BH, Peterson RG. Acetaminophen overdose: incidence, diagnosis, and management in 416 patients. Pediatrics. 1978; 62(5, pt 2, suppl):898-903.
107. Smilkstein MJ, Knapp GL, Kulig KW et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988; 319:1557-62. (Pubitemid 19003420)
108. Smilkstein MJ, Douglas DR, Daya MR. Acetaminophen poisoning and liver function. N Engl J Med. 1994; 331:1310-1.
109. Galicia-Moreno M, Rodríguez-Rivera A, Reyes-Gordillo K et al. N-acetylcysteine prevents carbon tetrachloride-induced liver cirrhosis: role of liver transforming growth factor-beta and oxidative stress. Eur J Gastroenterol Hepatol. 2009; 21:908-14.
110. Valles EG, de Castro CR, Castro JA. N-acetyl cysteine is an early but also a late preventive agent against carbon tetrachloride-induced liver necrosis. Toxicol Lett. 1994; 71:87-95. (Pubitemid 24097444)
111. Montanini S, Sinardi D, Praticò C et al. Use of acetylcysteine as the life-saving antidote in Amanita phalloides (death cap) poisoning. Case report on 11 patients. Arzneimittelforschung. 1999; 49:1044-7. (Pubitemid 30013116)
112. Dell'Aglio DM, Sutter ME, Schwartz MD et al. Acute chloroform ingestion successfully treated with intravenously administered N-acetylcysteine. J Med Toxicol. 2010; 6:143-6.
113. Anderson IB, Mullen WH, Meeker JE et al. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med. 1996; 124:726-34. (Pubitemid 26117921)
114. Yarema MC, Johnson DW, Berlin RJ et al. Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. Ann Emerg Med. 2009; 54:606-14.
115. Acetadote (acetylcysteine) injection package insert. Nashville, TN: Cumberland Pharmaceuticals Inc.; 2011.
116. Prescott LF, Illingworth RN, Critchley JA et al. Intravenous N-acetylcysteine: still the treatment of choice for paracetamol poisoning. Br Med J. 1980; 280:46-7. (Pubitemid 10217228)
117. Heard K. A multicenter comparison of the safety of oral versus intravenous acetylcysteine for treatment of acetaminophen overdose. Clin Toxicol (Phila). 2010; 48:424-30.
118. Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008; 359:285-92.
119. Horowitz RS, Dart RC, Jarvie DR et al. Placental transfer of N-acetylcysteine following human maternal acetaminophen toxicity. J Toxicol Clin Toxicol. 1997; 35:447-51. (Pubitemid 27371415)
120. Selden BS, Curry SC, Clark RF et al. Transplacental transport of N-acetylcysteinein an ovine model. Ann Emerg Med. 1991; 20:1069-72.
121. Dart RC, Rumack BH. Patient-tailored acetylcysteine administration. Ann Emerg Med. 2007; 50:280-1. (Pubitemid 47259236)
122. Evans LE, Swainson CP, Roscoe P et al. Treatment of drug overdosage with naloxone, a specific narcotic antagonist. Lancet. 1973; 1:452-5.
123. Evans LE. Use of naloxone in opiate poisoning. Br Med J. 1973; 2:717.
124. Dixon R, Gentile J, Hsu HB et al. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol. 1987; 27:233-9. (Pubitemid 18026908)
125. Jorm CM, Stamford JA. Actions of morphine on noradrenaline efflux in the rat locus coeruleus are mediated via both opioid and alpha 2 adrenoceptor mechanisms. Br J Anaesth. 1995; 74:73-8.
126. Seger DL. Clonidine toxicity revisited. J Toxicol Clin Toxicol. 2002; 40:145-55. (Pubitemid 34755580)
127. Easley RB, Altemeier WA III. Central nervous system manifestations of an ibuprofen overdose reversed by naloxone. Pediatr Emerg Care. 2000; 16:39-41. (Pubitemid 30102109)
128. Roberge RJ, Francis EH III. Use of naloxone in valproic acid overdose: case report and review. J Emerg Med. 2002; 22:67-70. (Pubitemid 34061943)
129. Thanacoody HK. Chronic valproic acid intoxication: reversal by naloxone. Emerg Med J. 2007; 24:677-8. (Pubitemid 47343068)
130. Varon J, Duncan SR. Naloxone reversal of hypotension due to captopril overdose. Ann Emerg Med. 1991; 20:1125-7.
131. Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med. 2006; 20(suppl 1):S3-8. (Pubitemid 43871328)
132. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010; 112:226-38.
133. Sarton E, Teppema L, Dahan A. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine. Adv Exp Med Biol. 2008; 605:486-91.
134. Van Dorp E, Yassen A, Sarton E et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006; 105:51-7. (Pubitemid 44305191)
135. Yassen A, Olofsen E, van Dorp E et al. Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone: a study in healthy volunteers. Clin Pharmacokinet. 2007; 46:965-80. (Pubitemid 47548645)
136. Goldfrank L, Weisman RS, Errick JK et al. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med. 1986; 15:566-70. (Pubitemid 16052110)
137. Boyle PJ, Justice K, Krentz AJ et al. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab. 1993; 76:752-6. (Pubitemid 23086500)
138. Fasano CJ, O'Malley G, Dominici P et al. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med. 2008; 51:400-6. (Pubitemid 351400282)
139. Calello DP, Kelly A, Osterhoudt KC. Case files of the medical toxicology fellowship training program at the children's hospital of Philadelphia: a pediatric exploratory sulfonylurea ingestion. J Med Toxicol. 2006; 2:19-24.
140. McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med. 2000; 36:133-8. (Pubitemid 30667018)
141. Green RS, Palatnick W. Effectiveness of octreotide in a case of refractory sulfonylurea-induced hypoglycemia. J Emerg Med. 2003; 25:283-7. (Pubitemid 37324665)
142. Rath S, Bar-Zeev N, Anderson K et al. Octreotide in children with hypoglycaemia due to sulfonylurea ingestion. J Paediatr Child Health. 2008; 44:383-4. (Pubitemid 351677495)
143. Pelavin PI, Abramson E, Pon S et al. Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide. J Pediatr Endocrinol. 2009; 22:171-5.
144. Vallurupalli S. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure. Ann Pharmacother. 2010; 44:387-90.